Circio’s management hosted a webcast on Wednesday 17 April 2024, presenting new in vivo data that demonstrate superiority of circVec vs. mRNA-based expression.
The webast also included an update on Circio´s gene therapy R&D strategy and a summary of 2023 company financials
Circular RNA is a powerful new format for RNA therapeutics, and with our differentiated circVec platform we have a unique opportunity to take a leading role in this emerging space. We are rapidly building our technical capabilities to demonstrate the versatility and broad potential of our technology and put Circio in position to capture the significant potential of vector-delivered circRNA.
Circio aims to be the leader in deploying circular RNA to enhance gene therapy for genetic disease